Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Regeneron initiated with an Outperform at Wolfe Research
Wolfe Research analyst Alexandria Hammond initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Published ...
Unlocking future medicines: The crucial role of clinical trials
Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...
Gilead, Vertex initiated as new big biotech buys at Citi
Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
Citi initiates coverage on 5 new biotech stocks
Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...
FierceBiotech13h
Sensei Bio lays off 46% of staff, closes research site to fund phase 2 cancer trial
Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...
manilatimes14h
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company ...
2 Top Growth Stocks to Buy on the Dip
Eli Lilly has been making quite a bit of noise thanks to its work in diabetes and obesity. Investors turned on the company, ...